143 related articles for article (PubMed ID: 1921014)
21. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
22. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
23. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.
Scheid C; Young R; McDermott R; Fitzsimmons L; Scarffe JH; Stern PL
Cancer Immunol Immunother; 1994 Feb; 38(2):119-26. PubMed ID: 8306367
[TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
25. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
26. Granulocyte-macrophage colony-stimulating factor augments lymphokine-activated killer activity from pleural cavity mononuclear cells of lung cancer patients without malignant effusion.
Takahashi K; Sone S; Saito S; Kamamura Y; Uyama T; Ogura T; Monden Y
Jpn J Cancer Res; 1995 Sep; 86(9):861-6. PubMed ID: 7591964
[TBL] [Abstract][Full Text] [Related]
27. Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.
Brooks B; Parry H; Lawry J; Rees R
Immunology; 1992 Feb; 75(2):343-8. PubMed ID: 1551696
[TBL] [Abstract][Full Text] [Related]
28. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro.
Hancock GE; Molloy A; Ab BK; Kiessling R; Becx-Bleumink M; Cohn ZA; Kaplan G
Cell Immunol; 1991 Feb; 132(2):277-84. PubMed ID: 1988157
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of recombinant interferons alpha, beta, and gamma on induction of human lymphokine (IL-2)-activated killer activity.
Sone S; Utsugi T; Nii A; Ogura T
J Natl Cancer Inst; 1988 May; 80(6):425-31. PubMed ID: 3130488
[TBL] [Abstract][Full Text] [Related]
31. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma.
Kondo M; Nonomura N; Miki T; Kojima Y; Yokoyama M; Nakano E; Okuyama A
Oncology; 1998; 55(6):588-93. PubMed ID: 9778628
[TBL] [Abstract][Full Text] [Related]
33. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
34. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
[TBL] [Abstract][Full Text] [Related]
35. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
36. Augmentation by transferrin of IL-2-inducible killer activity and perforin production of human CD8+ T cells.
Nakamura A; Sone S; Nabioullin R; Sugihara K; Munekata M; Nishioka Y; Nii A; Ogura T
Clin Exp Immunol; 1993 Apr; 92(1):174-9. PubMed ID: 8467561
[TBL] [Abstract][Full Text] [Related]
37. IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin).
Lazenby AW; Roth JA; Owen-Schaub LB; Grimm EA
Cytokine; 1992 Nov; 4(6):479-87. PubMed ID: 1337985
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
[TBL] [Abstract][Full Text] [Related]
39. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
40. Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
Nakajima I; Ozaki M; Jinnai H; Shilayama Y; Hirohata T; Okuno K; Yasutomi M
Cancer Biother; 1993; 8(4):319-26. PubMed ID: 7804373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]